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Abstract  
 
Background: Measurement of flecainide is useful to optimize dosage and minimise the risks 
of toxicity. Further, there is a need for urgent sample analysis when flecainide is used in 
transplacental therapy for foetal tachycardia. To this end, we have developed and validated a 
rapid assay for the measurement of flecainide in human plasma or serum, using a small sample 
volume (50 µL).  
Method: Following a simple deproteination with zinc sulphate and methanol, prepared 
samples were injected onto a short (30 mm) analytical column, and eluted using a rapid gradient 
elution. Detection was carried out using time-of-flight mass-spectrometry. Flecainide was 
quantified using flecainide-D4 as internal standard, with both compounds extracted from the 
total-ion chromatogram using a ± 5 ppm extraction window based on theoretical m/z values for 
the protonated ions.  
Results: The assay was linear over a putative therapeutic range (100 - 1,000 µg/L). Between- 
and within-assay precision and accuracy were < 4.6 % and 94.8 - 110.0 %, respectively. Matrix 
effects were minimal, and were compensated for by flecainide-D4. There were no effects due 
to haemolysis or lipaemia, and no carryover was apparent. Total analysis time was just 1.2 
minutes (72 s). 
Conclusions: We have developed and validated a rapid method for the analysis of flecainide. 
The method is particularly suited to flecainide TDM, when analysing samples from mothers 
receiving flecainide for the treatment of foetal tachycardia. 
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Introduction 
Flecainide is a class 1C (Vaughan-Williams) anti-arrhythmic agent used in the treatment of 
both atrial and ventricular tachyarrhythmias.[1] It is also highly effective as an oral maternal 
transplacental therapy in foetal tachycardia (FT),[1, 2] though the risk of pro-arrhythmic effects 
in some patients have limited its use.[3] The clinical efficacy and the risk of adverse events are 
associated with plasma or serum flecainide concentrations, which do not always correlate 
well with the prescribed dose due to variability in renal and hepatic clearance. Adverse events 
have been associated with flecainide concentrations greater than 1,000 µg/L,[4, 5] and case 
reports are available of severe iatrogenic flecainide toxicity in neonates associated with 
dosing errors leading to elevated flecainide concentrations.[6, 7] The lower concentration limit 
associated with anti-arrhythmic effect is typically defined as 200 µg/L,[8] though more 
recently a limit of 300 µg/L has been suggested for patients with tachyarrhythmia.[9] 
Monitoring plasma or serum concentrations of the drug is therefore an important part of the 
management of patients receiving flecainide anti-arrhythmic therapy, to guide dosage 
adjustments to maximise clinical efficacy with minimal risk of adverse events.[8] 
 
To maximise the clinical benefits of therapeutic drug monitoring (TDM) analytical results 
should be available as soon as possible to allow rapid dose adjustments, if necessary. 
However, such assays are often considered ‘specialist’ tests, and are not routinely available in 
many settings, certainly as urgent tests. Even within specialist laboratories using liquid 
chromatography, lengthy sample preparation and chromatographic methods for flecainide 
have been used,[10-13] and are not suited to urgent analyses. In this paper, we report the 
validation of a simple, rapid, liquid chromatography time-of-flight mass-spectrometry (LC-
TOF-MS) method for total plasma flecainide, suitable for use for TDM, and for urgent 
analyses relevant during the treatment of FT.  
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Materials and methods 
Chemicals and reagents 
(±)-Flecainide acetate, zinc sulfate heptahydrate, isopropanol, ammonium formate, formic 
acid (LC-MS grade) and acetic acid were from Sigma Aldrich (Poole, UK). Methanol (LC-
MS grade) was from Rathburn (Walkerburn, Scotland). (±)-Flecainide-D4 acetate was from 
Alsachim (Strasbourg, France). Water was deionised, prepared in-house (<1.0 µS/cm). 
Analyte-free human plasma (lithium heparin and EDTA) and analyte-free human serum from 
individual donors were from Biological Speciality Corporation (Colmar, PA, USA). Calibrant 
and reference ion stock solutions for the TOF-MS were from Agilent Technologies (Santa 
Clara, CA, USA) and were diluted according to the manufacturer’s instructions prior to use. 
External quality assessment (EQA) samples were from the LGC Therapeutic Drugs scheme 
(LGC, Lancashire, UK). 
 
Chromatography  
A 1290 binary LC pump was used with a 1290 Infinity II™ autosampler (Agilent 
Technologies). Analysis was performed using a Raptor™ biphenyl column (30 x 2.1 mm, 2.7 
µm total particle size; Thames Restek, Saunderton, UK) held at 40 °C in a column oven 
(MCT 1290, Agilent Technologies). System eluents were as follows: eluent A, 10 mmol/L 
ammonium formate in 0.01 % (v/v) formic acid in deionised water; eluent B, 10 mmol/L 
ammonium formate in 0.01 % (v/v) formic acid in methanol. Eluent B was also used as the 
autosampler needle wash solvent. The piston seal wash was 50 % (v/v) isopropanol in 
deionised water. Eluent flow was diverted to waste for the first 12 s of each analysis. Total 
analysis time was 72 seconds (1.2 min). 
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Mass-spectrometry 
A 6230 time-of-flight mass-spectrometer (Agilent Technologies) was used with a dual-spray 
electrospray ionisation source (Jet StreamTM, Agilent Technologies). Source conditions were: 
gas (high-purity nitrogen) temperature 325 °C, gas flow-rate 12 L/min, nebulizer gas pressure 
60 psig, sheath gas temperature 350 °C, sheath gas flow-rate 12 L/min, capillary voltage 
3,750 V. Instrument control and data acquisition were performed using MassHunter™ 
(version B.08.00, Agilent Technologies). TOF-MS data were acquired from 50—1,000 m/z. 
Acquisition rate was 5 scans per second (2,639 transients/spectrum). Mass calibration was 
carried out daily using calibration solution stored on the instrument, and reference ion 
solution (containing reference ions at m/z 121.0509 and 922.0098) was delivered throughout 
the analysis via the second nebuliser of the dual spray source at a constant flow rate using a 
1260 isocratic pump (Agilent Technologies), flowing at 1.00 mL/min with a 1:100 flow 
splitter (10 µL/min flow-rate at-source). 
For data processing, flecainide and flecainide-D4 (empirical formulae C17H20F6N2O3 and 
C17H16D4F6N2O3, respectively) chromatograms were extracted as protonated ions using ± 5 
ppm extraction windows (m/z 415.1451 and 419.1702 for flecainide and flecainide-D4, 
respectively). The naturally occurring 13C isotope of flecainide (m/z 416.1490) was used as a 
qualifier ion. The acceptance range for the extracted flecainide-13C peak area was 13.5 - 
22.5% that of the flecainide peak area. 
 
Sample preparation 
Samples, calibrators, and control solutions were thawed, if necessary, and mixed at room 
temperature by inversion. Samples, calibrators, and controls (50 µL) and working internal 
standard solution (50 µL) were pipetted into 1.5 mL micro-centrifuge tubes. Freshly prepared 
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precipitation reagent (0.2 mol/L aqueous zinc sulfate solution in methanol, 2 + 8, v/v) was 
then added. The tubes were capped and vortex mixed (60 s), prior to centrifugation (13,200 
rpm, 5 min). Supernatants were transferred with disposable pipettes to reduced-volume auto-
sampler vials, and capped for LC-TOF-MS analysis. The LC auto-sampler tray was cooled to 
10 °C, and 1 µL was injected for analysis.  
 
Calibrators, internal quality control (IQC), and internal standard solutions 
Calibrator and IQC stock solutions (both 100 mg/L flecainide) were prepared in methanol, 
and were stored frozen (-18 to -20 °C). Calibrators were prepared by appropriate dilution of 
the calibrator stock solution with analyte-free human plasma to contain 100, 250, 500, 750, 
1,000 and 1,500 µg/L flecainide. IQC solutions were similarly prepared by appropriate 
dilution of the IQC stock solution, prepared from a separate weighing, with analyte-free 
human plasma to contain 200, 400 and 800 µg/L flecainide. Once prepared, calibrators and 
IQC solutions were allowed to equilibrate overnight (2 to 8 °C) and were then aliquoted into 
approximately 250 µL portions in 1.5 mL micro-centrifuge tubes, which were stored frozen (-
18 to -20 °C) until required for analysis. 
 
Flecainide-D4 stock solution (approximately 100 mg/L) was prepared in methanol, and stored 
frozen (-18 to -20 °C). Working internal standard solution (approximately 500 µg/L) was 
prepared by 1+199 (v/v) dilution of the flecainide-D4 stock solution with 0.5 % (v/v) aqueous 
acetic acid. Working internal standard solution was stored at 2 to 8 °C. In addition, a system 
suitability test (SST) solution was prepared in methanol containing flecainide (50 µg/L). This 
was stored at 2 to 8 °C, and portions were transferred to auto-sampler vials for direct analysis 
prior to starting batch analysis, in order to check instrument performance. 
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Method validation 
Within-batch precision (% RSD) and accuracy were assessed by replicate analysis (N = 10) 
of the two IQC solutions, plus the lower limit of quantitation (LLoQ) and upper limit of 
quantitation (ULoQ) calibrators (100 µg/L and 1,500 µg/L, respectively). Between-batch 
precision and accuracy were assessed using the mean result (from at least duplicate analyses 
within each batch) given by the two IQC samples, and by the LLoQ and ULoQ calibrators on 
separate days (N = 10 batches) over a three-week period.  
Carryover was assessed using a high-concentration sample prepared in analyte-free plasma 
containing 5,000 µg/L flecainide (greater than three times the ULoQ calibrator). This sample 
was prepared and analysed bracketed by triplicate analyte-free plasma samples, and carryover 
was assessed by comparison of the flecainide peak areas in the samples before and after the 
high-concentration samples.  
Linearity was assessed by serial dilutions (each 1 + 1, v/v with analyte-free plasma) of the 
ULoQ calibrator. Each diluted sample was analysed in triplicate within a single batch, and the 
accuracy (observed vs expected concentration) and precision of each dilution was calculated. 
Autosampler stability (10 °C) was assessed by preparation of a calibration curve, which was 
analysed (i) immediately, (ii) after 24 hours, and (iii) after 48 hours in the autosampler tray. 
Additional stability of flecainide in human plasma was assessed using the three IQC 
solutions. IQC solutions were prepared and stored in various conditions – at ambient 
temperature for one week, refrigerated (2 to 8 °C) for one week, after three freeze-thaw 
cycles, and after frozen long-term storage (-15 to -25 °C) for 9 months. Stability samples 
were analysed against freshly-prepared calibrators stored frozen (-15 to -25 °C) and thawed 
only once prior to analysis. 
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Matrix effects and analyte recovery were assessed quantitatively using pre- and post-
extraction spiking experiments as described by Matuzewski et al., at 200 and 500 µg/L for 
both flecainide and flecainide-D4.[14] Matrix effects were assessed using six independent 
analyte-free matrices (two EDTA plasma, two lithium heparin plasma and two serum 
matrices). The influence of lipaemia and haemolysis were assessed using mixing 
experiments.[15] Briefly, lipaemic and haemolysed samples were prepared containing 
flecainide at 1,500 µg/L. These samples were mixed in different proportions with analyte-free 
‘normal’ plasma (i.e. not lipaemic or haemolysed) containing flecainide at 100 µg/L to 
produce five-point curves. The mean measured concentrations were compared to the expected 
concentrations to assess any bias due to these factors.  
 
Samples  
Patient plasma samples (N = 60) and EQA samples (N = 8) that had been submitted for 
flecainide TDM were extracted using the method described here and analysed by LC-TOF-
MS. The results were compared (Analyse-It for Microsoft Excel, 2010 version) with those 
obtained using a previously validated manual liquid-liquid extraction, liquid chromatography-
tandem mass-spectrometry (LC-MS/MS) method (see Details, Supplemental Digital Content 
1, which briefly describes the LC-MS/MS method). All LC-MS/MS analyses were carried out 
within 3 days of the sample arriving in the laboratory, and subsequent LC-TOF-MS analysis 
within 80 days. Samples were stored at 2 to 8 °C between analyses.  
 
Results 
Example chromatograms for flecainide, flecainide-13C (qualifier ion) and flecainide-D4 are 
shown in Figure 1. Typical retention times were 43.7 and 43.5 s for flecainide and flecainide-
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D4, respectively, and the total analysis time was just 72 seconds. Calibration was linear 
(typical R2 > 0.98) over the range 100 - 1,500 µg/L (see Table, Supplemental Digital Content 
2, which summarises the serial dilution linearity test). Within-batch and between-batch 
precision (% RSD) and accuracy (% nominal concentrations) were < 4.6 % and 94.8—110.0 
%, respectively (Table 1).  
No carryover was observed (no peaks in the analyte-free samples analysed directly after 
triplicate analysis of the high-concentration sample), and prepared samples were stable when 
stored on the autosampler for 48 h (10 °C). Flecainide was stable in plasma under all 
conditions tested (Table 2). 
The mean (SD) overall process efficiency for flecainide was 111.7 (4.22) %, and the mean 
(SD) matrix effect was 104.2 (4.24) %, suggesting some ionisation enhancement. However, 
the mean (SD) relative process efficiency and matrix effect, based on flecainide peak areas 
relative to flecainide-D4 peak areas, was 99.7 (0.33) % and 99.8 (0.53) %, respectively. There 
were no differences in overall process efficiency or observed matrix effects between EDTA 
plasma, lithium heparin plasma, and serum matrices. There was no observed bias as a result 
of haemolysis or lipaemia (see Table, Supplemental Digital Content 3, which displays the 
results of the mixing experiments). 
Comparison of results (N = 62, inclusive of patient and EQA samples) acquired via the rapid 
LC-TOF-MS method with an existing LC-MS/MS method using liquid-liquid extraction gave 
excellent agreement (y = 0.9895x + 16.679; R2 = 0.9905). The mean (SD) bias between the 
methods was 12.3 (30.7) µg/L [3.7 (6.6) %]. 6 samples (5 patient samples and 1 EQA 
sample) contained flecainide below 100 µg/L (Figure 2). 
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Discussion  
We have developed and validated a simple, rapid, method for the quantitation of total 
flecainide in human plasma and serum, ideally suited to use for flecainide TDM. In 
particular, the method is suitable for rapid turn-around of samples from patients receiving 
flecainide for in utero treatment of FT, or from neonates, infants or children with 
tachyarrhythmias. With simplified sample preparation and rapid batch analysis using the 
described LC-TOF-MS method, urgent analyses can be carried out within approximately one 
hour of sample receipt.  
The method uses LC-TOF-MS, which is uncommon for TDM analyses, but which does offer 
some advantages over other, more common, techniques such as LC-MS/MS. The assay 
demonstrated linear calibration for flecainide analysis across the required concentration 
range, with no evidence of peak saturation or mass inaccuracy at higher concentrations. The 
sensitivity of the method was comparable to that of our previously validated method using 
LC-MS/MS, without requiring additional sample volume (which often is not possible for 
samples from neonates), and despite the much simpler sample preparation method. The two 
methods compared very well with one another, and the LC-TOF-MS method performed well 
for retrospective EQA sample analysis. 
Whereas LC-MS/MS uses product ions and product ion ratios for sensitivity and selectivity, 
LC-TOF-MS relies on high-resolution data acquisition. In this method, we also extracted the 
m/z for the naturally occurring 13C isotope of flecainide for use as a pseudo-qualifier ion. An 
alternative approach (in the absence of a quadrupole for fragmentation) would be to use a 
high source voltage to induce in-source fragmentation, and then to monitor a precursor and 
product ion (and ion ratio).  
 12 
For rapid methods in particular, there are additional benefits of using LC-TOF-MS, rather 
than targeted LC-MS/MS. Firstly, although the method described in this study is for a single 
analyte and IS, multiplexed analysis, i.e. the simultaneous analysis of multiple 
drugs/metabolites, is perhaps better suited to LC-TOF-MS than LC-MS/MS. With LC-
MS/MS, each additional compound requires an apportionment of the acquisition cycle-time 
(often referred to as ‘dwell time’). Ideally, each additional compound would require more 
than one transition to allow product ion ratio calculations, and a (co-eluting) internal 
standard.[16] Therefore, for each additional concurrent ion transition in LC-MS/MS, one must 
consider dwell-time in relation to the number of data points across a chromatographic peak 
for accurate quantitation – this may limit the number of simultaneous analytes which can be 
measured in a short chromatographic analysis. With LC-TOF-MS, the cycle-time is set by the 
TOF-MS scan-rate, irrespective of the number of components to be later extracted from the 
acquired MS data. 
A coincidental advantage of such rapid analysis is that of data file size. High-resolution MS 
data files are much larger than LC-MS/MS data files, but are directly proportional to the 
analysis time – by reducing the analysis time significantly, data storage and transfer becomes 
quicker and cheaper. 
In this study, we have reported a novel method for flecainide TDM. The method is 
significantly faster than previously published methods, e.g. more than 6 minutes faster per 
injection than the method recently reported by Mano et al.[17] Further, we have demonstrated 
for the first time the application of LC-TOF-MS for flecainide quantitation, and have 
highlighted the possible benefits of this approach for other analytes for which TDM is 
indicated. 
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Table and Figure legends: 
 
Table 1. Accuracy and precision data: analysis of the IQC solutions using LC-TOF-MS. 
Table 2. Summary stability data. 
 
Figure 1. Example chromatograms for an LLoQ calibrator (100 µg/L). Shown are (A) 
flecainide with, inset, the flecainide-13C qualifier ion chromatogram, and (B) flecainide-D4. 
Figure 2. Comparison between LC-MS/MS and LC-TOF-MS results (N = 55 patient samples 
– solid dots; N = 6 EQA samples - crosses). Shown are (top) a scatter plot and (bottom) a 
difference plot of the results produced by both methods. The scatter plot shows the line of 
identity (solid black line), and the correlation curve (dashed line). The difference plot shows 
the line of zero bias (solid black line), and the mean (± 95 % limits of agreement) bias (thick 
black dashed line and fine black dashed lines, respectively). 
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Table 1. Accuracy and precision data: analysis of the IQC solutions using LC-TOF-MS. 
 
Within-assay 
Flecainide IQC A IQC B IQC C LLoQ ULoQ 
Nominal (µg/L) 200 400 800 100 1,500 
Mean measured (µg/L) 200.3 413.5 819.5 102.1 1,421.2 
RSD (%) 2.83 4.09 1.12 3.11 4.64 
Accuracy (%) 100.2 103.4 102.4 102.1 94.8 
Between-assay 
Flecainide IQC A IQC B IQC C LLoQ ULoQ 
Nominal (µg/L) 200 400 800 100 1,500 
Mean measured (µg/L) 206.5 440.2 832.9 99.5 1,442.7 
RSD (%) 3.65 3.20 1.96 3.45 3.65 
Accuracy (%) 103.2 110.0 104.1 99.5 96.2 
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Table 2. Summary stability data. 
 
Autosampler stability (post-preparation, 10 °C, 48 h) 
Flecainide IQC A IQC B IQC C 
Nominal (µg/L) 200 400 800 
Mean measured (µg/L) 210 445.5 834.8 
RSD (%) 2.11 2.85 4.49 
Accuracy (%) 105.2 111.4 104.4 
Stability at ambient temperature (15—30 °C, one week) 
Flecainide IQC A IQC B IQC C 
Nominal (µg/L) 200 400 800 
Mean measured (µg/L) 199.7 446.5 842.2 
RSD (%) 2.22 2.01 2.09 
Accuracy (%) 99.9 111.6 105.3 
Stability stored cooled (2—8 °C, one week) 
Flecainide IQC A IQC B IQC C 
Nominal (µg/L) 200 400 800 
Mean measured (µg/L) 190.1 408.1 830.1 
RSD (%) 7.97 7.61 0.57 
Accuracy (%) 95.1 102.0 103.8 
Freeze-thaw stability (3 x freeze-thaw cycles) 
Flecainide IQC A IQC B IQC C 
Nominal (µg/L) 200 400 800 
Mean measured (µg/L) 208.9 448.1 849.3 
RSD (%) 1.28 1.33 2.01 
Accuracy (%) 104.5 112.0 106.1 
Long-term stability (-15 to -25 °C, 9 months) 
Flecainide IQC A IQC B IQC C 
Nominal (µg/L) 200 400 800 
Mean measured (µg/L) 196.9 405.8 843.0 
RSD (%) 5.96 7.30 8.84 
Accuracy (%) 98.5 101.4 105.4 
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Figure 1. Example chromatograms for an LLoQ calibrator (100 µg/L). Shown are (A) 
flecainide with, inset, the flecainide-13C qualifier ion chromatogram, and (B) flecainide-D4. 
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Figure 2. Comparison between LC-MS/MS and LC-TOF-MS results (N = 55 patient samples 
– solid dots; N = 6 EQA samples - crosses). Shown are (top) a scatter plot and (bottom) a 
difference plot of the results produced by both methods. The scatter plot shows the line of 
identity (solid black line), and the correlation curve (dashed line). The difference plot shows 
the line of zero bias (solid black line), and the mean (± 95 % limits of agreement) bias (thick 
black dashed line and fine black dashed lines, respectively).  
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Supplemental Digital Content: 
 
Supplemental Digital Content 1. LC-MS/MS summary method details. 
 Supplemental Digital Content 1. docx file 
 
Supplemental Digital Content 2. Summary data from the serial dilution experiment to test 
assay linearity. 
 Supplemental Digital Content 2. docx file 
 
Supplemental Digital Content 3. Summary data from five-point mixing experiments to 
assess the influence of (A) haemolysis and (B) lipaemia. 
 Supplemental Digital Content 3. docx file 
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Supplemental Digital Content 1. Flecainide LC-MS/MS summary method information. 
 
Samples (50 µL) were prepared using a two-step liquid-liquid extraction, firstly into methyl-
tert-butyl ether, followed by a back-extraction into aqueous acetic acid. Prepared extracts 
were injected onto the LC-MS/MS system. 
 
LC-MS/MS was carried out using isocratic elution [300 µL/min, 2 mmol/L ammonium 
acetate and 0.1 % formic acid in deionised water and methanol (40 + 60, v/v)] on a reversed-
phase column (C18, 50 °C). Flecainide and flecainide-D4 eluted at 2.8 min, and the total 
analysis time was 5 minutes.  
 
MS/MS source conditions (API2000 mass spectrometer) were: turbo-heater temperature 400 
°C, curtain gas pressure 20 psig, collision gas pressure 6 psig, ionspray voltage 5,500 V. The 
pre-collision cell voltages were optimised for declustering potential (DP, 61 V), focusing 
potential (FP, 370 V), entrance potential (EP, 12 V), collision energy (CE, 41 V) and 
collision cell exit potential (CXP, 6 V).  
 
The flecainide/flecainide-D4 precursor ion and product ion were scanned at 415.122/419.140 
and 300.900/305.100 respectively. Instrument control and data acquisition were performed 
using AnalystTM (version 1.6.3, AB Sciex). 
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Supplemental Digital Content 2. Summary data from the serial dilution experiment to test 
assay linearity. 
 
Dilution 
from 
ULoQ 
(v/v) 
Mean measured 
concentration 
(µg/L, N = 3) 
SD (µg/L) RSD (%) 
Calculated 
(expected) 
concentrati
on (µg/L) 
Accuracy 
(%) 
N/A 1429.7 19.82 1.39 1429.7 - 
1+1 777.5 7.47 0.96 714.9 108.8 
1+3 386.4 3.53 0.91 357.4 108.1 
1+7 180.2 3.04 1.69 178.7 100.8 
1+15 82.45 4.16 5.04 89.4 92.3 
1+31 35.10 1.30 3.71 44.7 78.5 
1+63 10.82 1.41 13.06 22.3 48.4 
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Supplemental Digital Content 3. Summary data from five-point mixing experiments to 
assess the influence of (A) haemolysis and (B) lipaemia. 
 
(A) Haemolysis 
 
Sample ID 
Measured 
concentration 
(µg/L) 
Mean 
measured 
concentration 
(µg/L) 
Calculated 
(expected) 
concentration 
(µg/L) 
Accuracy 
(%) 
Neat ‘normal’ 
plasma, 100 µg/L 
101.02 
103.01 103.01 
98.1 
101.49 98.5 
110.90 107.7 
101.82 98.8 
99.82 96.9 
Mix 1 (3+1, v/v, 
normal plasma 
and haemolysed 
plasma) 
474.16 
483.15 476.06 
99.6 
479.24 100.7 
478.52 100.5 
481.27 101.1 
502.57 105.6 
Mix 2 (1+1, v/v, 
normal plasma 
and haemolysed 
plasma) 
909.55 
913.19 849.11 
107.1 
935.81 110.2 
906.55 106.8 
916.75 108.0 
897.31 105.7 
Mix 3 (1+3, v/v, 
normal plasma 
and haemolysed 
plasma) 
1331.65 
1281.83 1222.16 
109.0 
1340.57 109.7 
1249.77 102.3 
1246.55 102.0 
1240.62 101.5 
Neat haemolysed 
plasma, 1,500 
µg/L 
1625.53 
1595.21 1595.21 
101.9 
1587.32 99.5 
1609.61 100.9 
1565.50 98.1 
1588.11 99.6 
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(B) Lipaemia 
 
Sample ID 
Measured 
concentration 
(µg/L) 
Mean 
measured 
concentration 
(µg/L) 
Calculated 
(expected) 
concentration 
(µg/L) 
Accuracy 
(%) 
Neat ‘normal’ 
plasma, 100 µg/L 
94.44 
94.25 94.25 
100.2 
94.50 100.3 
93.44 99.1 
95.67 101.5 
93.22 98.9 
Mix 1 (3+1, v/v, 
normal plasma 
and lipaemic 
plasma) 
450.75 
475.63 457.77 
98.5 
484.36 105.8 
477.33 104.3 
483.26 105.6 
482.45 105.4 
Mix 2 (1+1, v/v, 
normal plasma 
and lipaemic 
plasma) 
845.18 
838.51 868.42 
97.3 
843.36 97.1 
839.37 96.7 
812.99 93.6 
851.67 98.1 
Mix 3 (1+3, v/v, 
normal plasma 
and lipaemic 
plasma) 
1205.95 
1201.42 1184.81 
101.8 
1190.83 100.5 
1190.47 100.5 
1196.31 101.0 
1223.57 103.3 
Neat lipaemic 
plasma, 1,500 
µg/L 
1539.83 
1548.33 1548.33 
99.5 
1548.39 100.0 
1555.15 100.4 
1571.83 101.5 
1526.44 98.6 
 
 
 
